Last reviewed · How we verify
NCT07400289: M149
Development of a FibroScan Liver Examination Using a Single Probe
NA trial testing Research FibroScan in Liver Diseases in 309 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | Echosens |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 309 |
| Start date | 14 November 2025 |
| Primary completion | 30 November 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 4 locations across France, Hong Kong |
Drugs / interventions tested
- Research FibroScan
Conditions studied
- Liver Diseases — all drugs for Liver Diseases →
Sponsor
Echosens — full company profile →
Who can join
18 and older, any sex, with Liver Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an exploratory, international, prospective, interventional, multicenter clinical investigation that will take place in 1 Hong Kong site and 3 French sites and 309 adults patients will be included. The study objective is to assess the LSM reproducibility between the FibroScan examination performed with the Single Probe (SP) and the FibroScan examination performed with the reference probes (M and XL).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07400289
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Research FibroScan
Trials testing the same drug.
- NCT04747457 — Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination · NA · completed
Other recruiting trials for Liver Diseases
Currently open trials in the same condition.
- NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
- NCT06519331 — Development of a New Method for Liver Stiffness Measurement Using FibroScan · NA · recruiting
Other Echosens trials
Trials by the same sponsor.
- NCT07222813 — Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP) · NA · not yet recruiting
- NCT06877026 — FibroScan-Reproducibility and Repeatability Study · NA · completed
- NCT06519331 — Development of a New Method for Liver Stiffness Measurement Using FibroScan · NA · recruiting
- NCT05567328 — Validation of the New Vibration-guided FibroScan Examination · NA · completed
- NCT05122416 — Optimization of Spleen VCTE Examinations with FibroScan · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07400289 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Echosens
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07400289.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing